Pathophysiology of acquired von Willebrand disease: A concise review

European Journal of Haematology

Volumn 87, Issue 2, 2011, Pages 99-106

  Shetty, Shrimati ^a   Kasatkar, Priyanka ^a   Ghosh, Kanjaksha ^a  

^a KEM HOSPITAL   (India)

Author keywords

Acquired von Willebrand disease; Hypothyroidism; Lymphoproliferative disorders; Myeloproliferative disorders; Systematic lupus erythematosus; Tumors

Indexed keywords

CARDIOVASCULAR DISEASE; DRUG INDUCED DISEASE; HUMAN; HYPOTHYROIDISM; IMMUNE RESPONSE; LYMPHOPROLIFERATIVE DISEASE; MOLECULAR WEIGHT; MYELOPROLIFERATIVE DISORDER; NEOPLASM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SHEAR STRESS; VON WILLEBRAND DISEASE;

AUTOANTIBODIES; CARDIOVASCULAR DISEASES; HUMANS; HYPOTHYROIDISM; LYMPHOPROLIFERATIVE DISORDERS; MYELOPROLIFERATIVE DISORDERS; NEOPLASMS; PROTEIN MULTIMERIZATION; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 79960391165     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2011.01636.x     Document Type: Review

References (92)

1. Ikeda Y, Handa M, Kawano K, et al. The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. J Clin Invest 1991;87:1234-40.
2. Titani K, Kumar S, Takio K, Ericsson LH, Wade RD, Ashida K, Walsh KA, Chopek MW, Sadler JE, Fujikawa K. Amino acid sequence of human von Willebrand factor. Biochemistry 1986;25:3171-84.
3. Dong JF, Moake JL, Bernardo A, Fujikawa K, Ball C, Nolasco L, López JA, Cruz MA. ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor. J Biol Chem 2003;278:29633-9.
4. ISTH-SSC VWF Online Database. Available at:, Accessed on 18/03/2011.
5. Wagner DD, Marder VJ. Biosynthesis of von Willebrand protein by human endothelial cells: processing steps and their intracellular localization. J Cell Biol 1984;99:2123-30.
6. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987;69:454-9.
7. Budde U, Bergmann F, Michiels JJ. Acquired von Willebrand syndrome: experience from 2years in a single laboratory compared with data from the literature and an international registry. Semin Thromb Hemost 2002;28:227-38.
8. Franchini M, Lippi G. Acquired von Willebrand syndrome: an update. Am J Hematol 2007;82:368-75.
9. Federici AB, Rand JH, Bucciarelli P, Budde U, van Genderen PJ, Mohri H, Meyer D, Rodeghiero F, Sadler JE. Subcommittee on von Willebrand factor. Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost 2000;84:345-9.
10. Federici AB. Acquired von Willebrand syndrome: is it an extremely rare disorder or do we see only the tip of the iceberg? J Thromb Haemost 2008;6:565-8.
11. Kumar S, Kishore R, Gupta V, Jain M, Shukla J. Prevalence and spectrum of von Willebrand disease in Eastern Uttar Pradesh. Indian J Pathol Microbiol 2010;53:486-9.
12. Srivastava A, Rodeghiero F. Epidemiology of von Willebrand disease in developing countries. Semin Thromb Hemost 2005;31:569-76.
13. Trasi S, Shetty S, Ghosh K, Mohanty D. Prevalence and spectrum of von Willebrand disease from western India. Indian J Med Res 2005;121:653-8.
14. Shetty S, Bhave M, Ghosh K. Acquired hemophilia A: diagnosis, etiology, clinical spectrum and treatment options. Autoimmun Rev 2011;10:311-6.
15. Michiels JJ, Budde U, van der Planken M, van Vliet HH, Schroyens W, Berneman Z. Acquired von Willebrand syndromes: clinical features, etiology, pathophysiology, classification and management. Best Pract Res Clin Haematol 2001;14:401-36.
16. Federici AB. Acquired von Willebrand syndrome associated with hypothyroidism: a mild bleeding disorder to be further investigated. Semin Thromb Hemost 2011;37:35-40.
17. Crow S, Chen D, Milano C, et al. Acquired von Willebrand syndrome in continuous-flow ventricular assist device recipients. Ann Thorac Surg 2010;90:1263-9.
18. Federici AB. Acquired von Willebrand syndrome: an underdiagnosed and misdiagnosed bleeding complication in patients with lymphoproliferative and myeloproliferative disorders. Semin Hematol 2006;43:S48-58.
19. Veyradier A, Jenkins CS, Fressinaud E, Meyer D. Acquired von Willebrand syndrome: from pathophysiology to management. Thromb Haemost 2000;84:175-82.
20. Mohri H. Acquired von Willebrand syndrome: its pathophysiology, laboratory features and management. J Thromb Thrombolysis 2003;15:141-9.
21. Lamboley V, Zabraniecki L, Sie P, Pourrat J, Fournié B. Myeloma and monoclonal gammopathy of uncertain significance associated with acquired von Willebrand's syndrome. Seven new cases with a literature review. Joint Bone Spine 2002;69:62-7.
22. Mohri H, Tanabe J, Ohtsuka M, Yoshida M, Motomura S, Nishida S, Fujimura Y, Okubo T. Acquired von Willebrand disease associated with multiple myeloma; characterization of an inhibitor to von Willebrand factor. Blood Coagul Fibrinolysis 1995;6:561-6.
23. Mazurier C, Parquet-Gernez A, Descamps J, Bauters F, Goudemand M. Acquired von Willebrand's syndrome in the course of Waldenström's disease. Thromb Haemost 1980;44:115-8.
24. Jonge Poerink-Stockschlader AB, Dekker I, Risseeuw-Appel IM, Hählen K. Acquired Von Willebrand disease in children with a Wilms' tumor. Med Pediatr Oncol 1996;26:238-43.
25. van Genderen PJ, Michiels JJ, Bakker JJ, van't Veer MB. Effectiveness of high-dose intravenous gamma globulin therapy in acquired von Willebrand's disease. Vox Sang 1994;67:14-7.
26. Roussi JH, Houbouyan LL, Alterescu R, Franc B, Goguel AF. Acquired Von Willebrand's syndrome associated with hairy cell leukaemia. Br J Haematol 1980;46:503-6.
27. Mohri H. Acquired von Willebrand syndrome: features and management. Am J Hematol 2006;81:616-23.
28. Facon T, Caron C, Courtin P, Wurtz A, Deghaye M, Bauters F, Mazurier C, Goudemand J. Acquired type II von Willebrand's disease associated with adrenal cortical carcinoma. Br J Haematol 1992;80:488-94.
29. Rolf N, Suttorp M, Budde U, Siegert G, Knoefler R. Essential thrombocythaemia in a teenage girl resulting in acquired von Willebrand syndrome with joint haemorrhage and menorrhagia. Thromb Haemost 2010;103:1272-4.
30. Giannini S, Solimando M, Fierro T, Baronciani L, Federici AB, Gresele P. Acquired von Willebrand syndrome type 2A in a JAK2-positive essential thrombocythaemia-affected member of a large von Willebrand disease family with a novel autosomal dominant A1716P mutation. Thromb Haemost 2011;105:921-4.
31. Tefferi A, Smock KJ, Divgi AB. Polycythemia vera-associated acquired von Willebrand syndrome despite near-normal platelet count. Am J Hematol 2010;85:545.
32. Landolfi R, Cipriani MC, Novarese L. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia. Best Pract Res Clin Haematol. 2006;19:617-33.
33. Uchiyama M, Ikeda T. Successful imatinib mesylate therapy for acquired von Willebrand syndrome in chronic myelogenous leukemia. Leuk Res 2009;33:1723-4.
34. Mohri H, Tanabe J, Yamazaki E, Yoshida M, Harano H, Matsuzaki M, Motomura S, Okubo T. Acquired type 2A von Willebrand disease in chronic myelocytic leukemia. Hematopathol Mol Hematol 1996;10:123-33.
35. Mohri H. Acquired von Willebrand disease in patients with polycythemia rubra vera. Am J Hematol 1987;26:135-46.
36. Sánchez-Luceros A, Meschengieser SS, Woods AI, Blanco AN, Kempfer AC, Casais P, et al. Acquired von Willebrand factor abnormalities in myeloproliferative disorders and other hematologic diseases: a retrospective analysis by a single institution. Haematologica 2002;87:264-70.
37. Mohri H, Motomura S, Kanamori H, Matsuzaki M, Watanabe S, Maruta A, Kodama F, Okubo T. Clinical significance of inhibitors in acquired von Willebrand syndrome. Blood 1998;91:3623-9.
38. van Genderen PJ, Budde U, Michiels JJ, van Strik R, van Vliet HH. The reduction of large von Willebrand factor multimers in plasma in essential thrombocythemia is related to the platelet count. Br J Haematol 1996;93:962-5.
39. Budde U, Scharf RE, Franke P, Hartmann-Budde K, Dent J, Ruggeri ZM. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood 1993;82:1749-57.
40. Tatewaki W, Takahashi H, Shibata A. Multimeric composition of plasma von Willebrand factor in chronic myeloproliferative disorders. Clin Lab Haematol 1988;10:417-25.
41. Lazarchick J, Pappas AA, Kizer J, Hall SA. Acquired von Willebrand syndrome due to an inhibitor specific for von Willebrand factor antigens. Am J Hematol 1986;21:305-14.
42. Mohri H, Ohkubo T. Acquired von Willebrand's syndrome due to an inhibitor of IgG specific for von Willebrand's factor in polycythemia rubra vera. Acta Haematol 1987;78:258-64.
43. Michiels JJ, Berneman Z, Schroyens W, Finazzi G, Budde U, van Vliet HH. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost 2006;32:589-604.
44. Gill JC, Wilson AD, Endres-Brooks J, Montgomery RR. Loss of the largest von Willebrand factor multimers from the plasma of patients with congenital cardiac defects. Blood 1986;67:758-61.
45. Massyn MW, Khan SA. Heyde syndrome: a common diagnosis in older patients with severe aortic stenosis. Age Ageing 2009;38:267-70.
46. Warkentin TE, Moore JC, Anand SS, Lonn EM, Morgan DG. Gastrointestinal bleeding, angiodysplasia, cardiovascular disease, and acquired von Willebrand syndrome. Transfus Med Rev 2003;17:272-86.
47. Heilmann C, Geisen U, Beyersdorf F, Nakamura L, Benk C, Berchtold-Herz M, Trummer G, Schlensak C, Zieger B. Acquired von Willebrand syndrome in patients with ventricular assist device or total artificial heart. Thromb Haemost 2010;103:962-7.
48. Geisen U, Heilmann C, Beyersdorf F, Benk C, Berchtold-Herz M, Schlensak C, Budde U, Zieger B. Non-surgical bleeding in patients with ventricular assist devices could be explained by acquired von Willebrand disease. Eur J Cardiothorac Surg 2008;33:679-84.
49. Fressinaud E, Meyer D. International survey of patients with von Willebrand disease and angiodysplasia. Thromb Haemost 1993;70:546.
50. Banerjee AK. Angiodysplasia associated with hypertrophic obstructive cardiomyopathy (HOCM). Br J Clin Pract 1990;44:326-7.
51. Meyer AL, Malehsa D, Bara C, Budde U, Slaughter MS, Haverich A, Strueber M. Acquired von Willebrand syndrome in patients with an axial flow left ventricular assist device. Circ Heart Fail 2010;3:675-81.
52. Heilmann C, Geisen U, Beyersdorf F, Nakamura L, Benk C, Berchtold-Herz M, Trummer G, Schlensak C, Zieger B. Acquired von Willebrand syndrome in patients with ventricular assist device or total artificial heart. Thromb Haemost 2010;103:962-7.
53. Pereira NL, Chen D, Kushwaha SS, Park SJ. Discontinuation of antithrombotic therapy for a year or more in patients with continuous-flow left ventricular assist devices. Interact Cardiovasc Thorac Surg 2010;11:503-5.
54. Vincentelli A, Susen S, Le Tourneau T, et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 2003;349:343-9.
55. Sadler JE. Aortic stenosis, von Willebrand factor, and bleeding. N Engl J Med 2003;349:323-5.
56. Simone JV, Cornet JA, Abildgaard CF. Acquired von Willebrand's syndrome in systemic lupus erythematosus. Blood 1968;31:806-12.
57. Sampson BM, Greaves M, Malia RG, Preston FE. Acquired von Willebrand's disease: demonstration of a circulating inhibitor to the factor VIII complex in four cases. Br J Haematol 1983;54:233-44.
58. Yoshida H, Arai K, Wakashin M. Development of acquired von Willebrand's disease after mixed connective tissue disease. Am J Med 1988;85:445-6.
59. Mazurier C, Parquet-Gernez A, Descamps J, Bauters F, Goudemand M. Acquired von Willebrand's syndrome in the course of Waldenström's disease. Thromb Haemost 1980;44:115-8.
60. Mohri H, Tanabe J, Yamazaki E, Yoshida M, Harano H, Matsuzaki M, Motomura S, Okubo T. Acquired type 2A von Willebrand disease in chronic myelocytic leukemia. Hematopathol Mol Hematol 1996;10:123-33.
61. Inbal A, Bank I, Zivelin A, Varon D, Dardik R, Shapiro R, Rosenthal E, Shenkman B, Gitel S, Seligsohn U. Acquired von Willebrand disease in a patient with angiodysplasia resulting from immune-mediated clearance of von Willebrand factor. Br J Haematol 1997;96:179-82.
62. Kumar S, Pruthi RK, Nichols WL. Acquired von Willebrand disease. Mayo Clin Proc 2002;77:181-7.
63. Meyer D, Frommel D, Larrieu MJ, Zimmerman TS. Selective absence of large forms of factor VIII/von Willebrand factor in acquired von Willebrand's syndrome. Response to transfusion. Blood 1979;54:600-6.
64. Lazarchick J, Green C. Acquired von Willebrand's disease following bone marrow transplantation. Ann Clin Lab Sci 1994;24:211-5.
65. van Genderen PJ, Vink T, Michiels JJ, van't Veer MB, Sixma JJ, van Vliet HH. Acquired von Willebrand disease caused by an autoantibody selectively inhibiting the binding of von Willebrand factor to collagen. Blood 1994;84:3378-84.
66. Goudemand J, Samor B, Caron C, Jude B, Gosset D, Mazurier C. Acquired type II von Willebrand's disease: demonstration of a complexed inhibitor of the von Willebrand factor-platelet interaction and response to treatment. Br J Haematol 1988;68:227-33.
67. Vescovi PP, Favaloro EJ, Lippi G, Garofano M, Montagnana M, Manzato F, Franchini M. The spectrum of coagulation abnormalities in thyroid disorders. Semin Thromb Hemost 2011;37:7-10.
68. Targher G, Pichiri I, Zoppini G, Bonora E, Chonchol M. Hemostatic and fibrinolytic abnormalities in endocrine diseases: a narrative review. Semin Thromb Hemost 2009;35:605-12.
69. Manfredi E, van Zaane B, Gerdes VE, Brandjes DP, Squizzato A. Hypothyroidism and acquired von Willebrand's syndrome: a systematic review. Haemophilia 2008;14:423-33.
70. Baumgartner-Parzer SM, Wagner L, Reining G, Sexl V, Nowotny P, Müller M. Increase by tri-iodothyronine of endothelin-1, fibronectin and von Willebrand factor in cultured endothelial cells. J Endocrinol 1997;154:231-9.
71. Franchini M, Zugni C, Veneri D, Gandini G, Lippi G, Manzato F, Brazzarola P. High prevalence of acquired von Willebrand's syndrome in patients with thyroid diseases undergoing thyroid surgery. Haematologica 2004;89:1341-6.
72. Noronha PA, Hruby MA, Maurer HS. Acquired von Willebrand disease in a patient with Wilms tumor. J Pediatr 1979;95:997-9.
73. Jonge Poerink-Stockschlader AB, Dekker I, Risseeuw-Appel IM, Hählen K. Acquired Von Willebrand disease in children with a Wilms' tumor. Med Pediatr Oncol 1996;26:238-43.
74. Han P, Lou J, Wong HB. Wilms' tumor with acquired von Willebrand's disease. Aust Paediatr J 1987;23:253-5.
75. Holland L, Adamson A, Ingram GI, Chalmers DG. Acquired von Willebrand's syndrome. Br J Haematol 1980;45:161-4.
76. Nowak-Göttl U, Kehrel B, Budde U, Hoffmann C, Winkelmann W, Jürgens H. Acquired von Willebrand disease in malignant peripheral neuroectodermal tumor (PNET). Med Pediatr Oncol 1995;25:117-8.
77. Elli M, Pinarli FG, Dagdemir A, Dabak N, Fisgin T, Selcuk MB. Acquired von Willebrand syndrome in a patient with Ewing sarcoma. Pediatr Hematol Oncol 2006;23:111-4.
78. Scrobohaci ML, Daniel MT, Levy Y, Marolleau JP, Brouet JC. Expression of GpIb on plasma cells in a patient with monoclonal IgG and acquired von Willebrand disease. Br J Haematol 1993;84:471-5.
79. Michiels J, Schroyens W, Berneman Z, van der Planken M. Atypical variant of acquired von Willebrand syndrome in Wilms tumor: is hyaluronic acid secreted by nephroblastoma cells the cause?. Clin Appl Thromb Hemost 2001;7:102-5.
80. Dalrymple-Hay M, Aitchison R, Collins P, Sekhar M, Colvin B. Hydroxyethyl starch induced acquired von Willebrand's disease. Clin Lab Haematol 1992;14:209-11.
81. Jonville-Béra AP, Autret-Leca E, Gruel Y. Acquired type I von Willebrand's disease associated with highly substituted hydroxyethyl starch. N Engl J Med 2001;345:622-3.
82. Serdaroglu G, Tütüncüoglu S, Kavakli K, Tekgül H. Coagulation abnormalities and acquired von Willebrand's disease type 1 in children receiving valproic acid. J Child Neurol 2002;17:41-3.
83. Conrad ME, Latour LF. Acquired von Willebrand's disease, IgE polyclonal gammopathy and griseofulvin therapy. Am J Hematol 1992;41:143.
84. Castaman G, Lattuada A, Mannucci PM, Rodeghiero F. Characterization of two cases of acquired transitory von Willebrand syndrome with ciprofloxacin: evidence for heightened proteolysis of von Willebrand factor. Am J Hematol 1995;49:83-6.
85. Rock G, Adamkiewicz T, Blanchette V, Poon A, Sparling C. Acquired von Willebrand factor deficiency during high-dose infusion of recombinant factor VIII. Br J Haematol 1996;93:684-7.
86. Federici AB, Berkowitz SD, Lattuada A, Mannucci PM. Conditions in which there is heightened proteolysis Degradation of von Willebrand factor in patients with acquired clinical. Blood 1993;81:720-5.
87. van Den Brink WA, van Genderen P, Thijsse WJ, Michiels JJ. Hetastarch coagulopathy. J Neurosurg 1996;85:367.
88. Jonville-Béra AP, Autret-Leca E, Gruel Y. Acquired type I von Willebrand's disease associated with highly substituted hydroxyethyl starch. N Engl J Med 2001;345:622-3.
89. Stump DC, Strauss RG, Henriksen RA, Petersen RE, Saunders R. Effects of hydroxyethyl starch on blood coagulation, particularly factor VIII. Transfusion 1985;25:349-54.
90. Kinoshita S, Yoshioka K, Kasahara M, Takamiya O. Acquired von Willebrand disease after Epstein-Barr virus infection. J Pediatr 1991;119:595-8.
91. Benson PJ, Peterson LC, Hasegawa DK, Smith CM II. Abnormality of von Willebrand factor in patients with hemoglobin E-beta (0) thalassemia. Am J Clin Pathol 1990;93:395-9.
92. McGrath KM, Johnson CA, Stuart JJ. Acquired von Willebrand disease associated with an inhibitor to factor VIII antigen and gastrointestinal telangiectasia. Am J Med 1979;67:693-6.